A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
← catalyst calendarNCT07276581 · readout in 450 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
320estimated
Sites
144
Countries
Argentina, Brazil, Bulgaria +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-15 | actual | When the study began enrolling |
| Primary completion | 2027-11-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-18 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rheumatoid Arthritis
Interventions
- Drug: AZD1163
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12
measured Week 12
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed